The vision of the CAG in Translational Hematology is to improve the outcome of treatment for patients with blood cancer.
The initially focus is on acute myeloid leukemia (AML) and myeloid dysplastic syndrome (MDS), with the aim to expand the work to other types of blood cancer.
The CAG is build on ongoing collaborations between leading basic and clinical researchers in the field, securing fast impact of the CAG.
A closer collaboration between researchers and clinicians dealing with blood cancer is of great importance for research and treatment in the field of hematology. This applies today but also in the longer term, where we will find new drugs to treat the patients with. The formal collaboration established with CHSP makes it easier to convey the basic research into clinical research, as well as providing the physicians with a better understanding of new treatment methods that are being used and can be used in the future. In addition, the collaboration allows patients to participate in some clinical trials, in which they could not participate in before.
- Have an immediate impact on how blood cancer patients are treated today
- Improve the understanding of genetic, epigenetic and molecular mechanisms leading to blood cancers
- Suggest new validated targets for the development of anti-cancer therapy
- Strengthen both the short- and long-term research and clinical management of blood cancer
- Strengthen collaborations with the pharma industry to develop new drugs for the treatment of blood cancers
The CAG will work on improving the translational education of the next generation of clinicians and scientists working collaboratively on blood cancers to have a long-lasting impact on how blood cancer patients are treated.